On October 4th 2023, the Oncologic Drugs Advisory Committee [ODAC] will discuss new drug application (NDA) 215500, for eflornithine tablets, submitted by USWM, LLC. The proposed indication (use) for this product is to reduce the risk of relapse in pediatric patients with high-risk neuroblastoma who have completed multiagent, multimodality therapy.
Back to All Events
Earlier Event: September 27
Cellular, Tissue, and Gene Therapies Advisory Committee
Later Event: October 5
Vaccines and Related Biological Products Advisory Committee